Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma

Abstract

AimsLiver hepatocellular carcinoma (LIHC) is the main manifestation of primary liver cancer, with low survival rate and poor prognosis. Medical decision-making process of LIHC is so complex that new biomarkers for diagnosis and prognosis have yet to be explored, this study aimed to identify the genes involved in the pathophysiology of LIHC and biomarkers that can be used to predict the prognosis of LIHC.MethodsSix Gene Expression Omnibus (GEO) datasets selected from GEO were screened and integrated to find out the differential expression genes (DEGs) obtained from LIHC and normal hepatic tissues. The Gene Ontology and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment analysis of DEGs was implemented by DAVID. The Protein–protein interaction network was performed via STRING. In addition, Cox regression model was used to construct a gene prognostic signature.ResultsWe ascertained 10 hub genes, nine of them (CDK1, CDC20, CCNB1, Thymidylate synthetase, Nuclear division cycle80, NUF2, MAD2L1, CCNA2 and BIRC5) as biomarkers of progression in LIHC patients. We also build a six gene prognosis signature (SOCS2, GAS2L3, NLRP5, TAF3, UTP11 and GAGE2A), which can be implemented to predict over survival effectively.ConclusionsWe revealed promising genes that may participate in the pathophysiology of LIHC, and found available biomarkers for LIHC prognosis prediction, which were significant for researchers to further understand the molecular basis of LIHC and direct the synthesis medicine of LIHC.

Clinical Value for Diagnosis and Prognosis of Signal Sequence Receptor 1 (SSR1) and Its Potential Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on High-Throughput Data Analysis

“…3,4 It has the characteristics of poor prognosis, high recurrence rate, and low survival rate. 5 As reported, the five-year survival rate can even be as low as 18%, while the recurrence rate is as high as 60% ~70%. 6 Currently, clinical strategies including liver transplantation, surgical resection, and chemotherapy seem to bring greater clinical benefits to patients with early HCC, while their application in advanced HCC cases is limited.…”

An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation

“…Inhibition of BIRC5 improves cervical cancer cell sensitivity to radiotherapy [ 29 ]. Nine genes, including BIRC5, may be biomarkers for HCC [ 30 ]. FKBP1a encodes proteins that are members of the immunomodulatory family, and it is pivotal in immunomodulatory and fundamental cellular processes involved in protein folding and transport.…”

Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma

“…Liver cancer is the fifth most common cancer worldwide, and liver hepatocellular carcinoma (HCC) is the main manifestation of primary liver cancer with low survival rate, high recurrence rate and poor prognosis [1,2]. Accounting for 70% to 90% of all pathological types, HCC is one of the most common…”